Alterations of JNK Signaling Pathway Activity in the Rat Retina: Effects of Age, Age-Related Macular Degeneration-like Pathology, and a JNK Inhibitor (IQ-1S)

Cells. 2025 Jun 13;14(12):896. doi: 10.3390/cells14120896.

Abstract

Age-related macular degeneration (AMD) is the leading cause of irreversible visual impairment worldwide. AMD development is associated with inflammation, oxidative stress, and a progressive proteostasis imbalance, in whose regulation, c-Jun N-terminal kinases (JNKs) play a crucial role. JNK inhibition is being discussed as a new way to prevent and treat AMD, but there are no data on JNK signaling in the retina and its changes with age and with AMD development. Here, for the first time, we assessed JNK-signaling activity in the retina and did not detect its age-related changes in healthy Wistar rats. By contrast, manifestation and progression of the AMD-like pathology in OXYS rats occurred simultaneously with JNK pathway activation. We also confirmed that selective JNK3 inhibitor 11H-indeno[1,2-b]quinoxalin-11-one oxime sodium salt (IQ-1S) can suppress neurodegenerative changes in the OXYS rat retina. Its effects were prevention of the destructive changes in retinal synapses and the suppression of the JNK signaling pathway activity during active progression of AMD signs in OXYS rats.

Keywords: IQ-1S; JNK inhibitor; JNK signaling; OXYS rats; age; age-related macular degeneration; retina; synapses.

MeSH terms

  • Aging* / metabolism
  • Aging* / pathology
  • Animals
  • Disease Models, Animal
  • MAP Kinase Signaling System* / drug effects
  • Macular Degeneration* / drug therapy
  • Macular Degeneration* / metabolism
  • Macular Degeneration* / pathology
  • Male
  • Oximes* / pharmacology
  • Protein Kinase Inhibitors* / pharmacology
  • Quinoxalines* / pharmacology
  • Rats
  • Rats, Wistar
  • Retina* / drug effects
  • Retina* / metabolism
  • Retina* / pathology

Substances

  • Quinoxalines
  • Protein Kinase Inhibitors
  • Oximes